. Author manuscript; available in PMC: 2014 Nov 7.

Published in final edited form as: JACC Heart Fail. 2014 Jun;2(3):260–268. doi: 10.1016/j.jchf.2013.12.004

Table 2.

Biomarkers and Risk According to of Mode of Death

Prediction Models	Pump Failure HR (95%CI)	Sudden Cardiac Death HR (95%CI)	Differential P value
Log₂ NT-proBNP univariate	3.71 (2.65–5.18)	1.95 (1.39–2.73)	<0.01
Adjusted for Clinical Model^*	2.85 (1.92–4.25)	1.97 (1.30–2.99)	0.21
Adjusted for Clinical Model^* + Galectin-3 + ST2	1.91 (1.24–2.95)	1.65 (1.06–2.58)	0.65

Galectin-3 Truncated at 20ng/dL univariate	2.77 (1.93–3.99)	1.68 (1.21–1.32)	0.04
Adjusted for Clinical Model^*	1.92 (1.27–2.93)	1.70 (1.12–2.58)	0.68
Adjusted for Clinical Model^*+ NT-proBNP	1.60 (1.05–2.42)	1.51 (0.99–2.30)	0.85
Adjusted for Clinical Model^*+ NT-proBNP + ST2	1.38 (0.90–2.11)	1.47 (0.96–2.25)	0.83

Log₂ ST2 univariate	2.37 (1.94–2.89)	1.66 (1.28–2.15)	0.03
Adjusted for Clinical Model^*	2.18 (1.69–2.81)	1.49 (1.10–2.01)	0.06
Adjusted for Clinical Model^*+ NT-proBNP	1.75 (1.31–2.35)	1.27 (0.90–1.78)	0.16
Adjusted for Clinical Model^*+ NT-proBNP + Galectin-3	1.67 (1.24–2.26)	1.22 (0.87–1.72)	0.17

HF-ACTION Clinical Adjustment Model: Serum creatinine level, Body Mass Index, Sex, Dosage of loop diuretic, Left Ventricular ejection fraction, CCS angina classification, and resting ECG Ventricular Conduction abnormality. NT-proBNP indicates amino-terminal proB-type natriuretic peptide; HR, hazard ratio; CI, confidence interval.